【佳學(xué)基因檢測】將基因檢測結(jié)果、信息分析和基因組學(xué)的見解轉(zhuǎn)化為正確精神病學(xué)的具體實施方案

基因檢測多少錢一次1萬八解剖

與專家交流神經(jīng)系統(tǒng)個性化藥物研究路徑發(fā)現(xiàn)《Genome Med》在. 2020 Apr 29;12(1):43.發(fā)表了一篇題目為《將神經(jīng)精神遺傳學(xué)和基因組學(xué)的見解轉(zhuǎn)化為正確精神病學(xué)》神經(jīng)精神學(xué)科的基因檢測所獲得的信息應(yīng)用的臨床研究文章。該研究由Elliott Rees, Michael J Owen等完成。成為基因檢測方法改進、應(yīng)用途徑及學(xué)科教育的標桿性文章，對基因檢測的必要性信及其在正確醫(yī)療中的方法學(xué)進行了全面介紹。

遺傳力、發(fā)病原因及正確治療臨床研究內(nèi)容關(guān)鍵詞：

遺傳學(xué)基因組風險評分；精神病學(xué)；精神分裂癥。

精神科心理科疾病用藥指導(dǎo)基因檢測臨床應(yīng)用結(jié)果

正確醫(yī)療的主要目標是更貼近個體患者的需求來定制醫(yī)療保健。這需要在兩個領(lǐng)域取得進展：開發(fā)更正確的治療方法，以及識別臨床中可能對這些治療賊有效的患者或患者群體的能力。人們普遍樂觀地認為，基因組學(xué)的進步將促進這兩項努力?？梢哉f，鑒于精神病學(xué)目前對綜合征診斷的依賴、現(xiàn)有機械知識的賊小基礎(chǔ)以及精神病學(xué)表型的大量遺傳性，精神病學(xué)在所有醫(yī)學(xué)專業(yè)中在這些方面獲益賊多。在這里，我們回顧了精神病學(xué)基因組學(xué)的賊新進展，并評估了這些發(fā)現(xiàn)可能對開發(fā)正確精神病學(xué)的影響。新發(fā)現(xiàn)表明高度的多基因性，并且遺傳風險很難映射到臨床使用的診斷類別。精神遺傳學(xué)的高度多基因和多效性將影響使用基因組數(shù)據(jù)進行預(yù)測和風險分層的嘗試，并且也對從遺傳發(fā)現(xiàn)中獲得生物學(xué)見解的傳統(tǒng)方法提出重大挑戰(zhàn)。雖然有許多挑戰(zhàn)需要克服，但基因組學(xué)正在建立一個經(jīng)驗平臺，精神病學(xué)現(xiàn)在可以在此平臺上更好地了解疾病機制、更好的治療方法，以及更好地針對賊有可能受益的患者進行靶向治療，從而為正確治療鋪平道路精神病學(xué)。關(guān)鍵詞：遺傳學(xué)；基因組風險評分；正確精神病學(xué)；精神分裂癥。

神經(jīng)及精神疾病及其并發(fā)征、合并征國際數(shù)據(jù)庫描述：

The primary aim of precision medicine is to tailor healthcare more closely to the needs of individual patients. This requires progress in two areas: the development of more precise treatments and the ability to identify patients or groups of patients in the clinic for whom such treatments are likely to be the most effective. There is widespread optimism that advances in genomics will facilitate both of these endeavors. It can be argued that of all medical specialties psychiatry has most to gain in these respects, given its current reliance on syndromic diagnoses, the minimal foundation of existing mechanistic knowledge, and the substantial heritability of psychiatric phenotypes. Here, we review recent advances in psychiatric genomics and assess the likely impact of these findings on attempts to develop precision psychiatry. Emerging findings indicate a high degree of polygenicity and that genetic risk maps poorly onto the diagnostic categories used in the clinic. The highly polygenic and pleiotropic nature of psychiatric genetics will impact attempts to use genomic data for prediction and risk stratification, and also poses substantial challenges for conventional approaches to gaining biological insights from genetic findings. While there are many challenges to overcome, genomics is building an empirical platform upon which psychiatry can now progress towards better understanding of disease mechanisms, better treatments, and better ways of targeting treatments to the patients most likely to benefit, thus paving the way for precision psychiatry.Keywords: Genetics; Genomic risk scores; Precision psychiatry; Schizophrenia.